2. (Cancelled) The composition according to claim 1 wherein the pharmaceutically acceptable carrier is selected from the group consisting of cocoa butter, aloe vera gel, aquafor, petroleum jelly, lecithin, almond oil, borage oil, canola oil, grape seed oil, jojoba oil, olive oil, soybean oil, sunflower oil, wheat germ oil, apricot kernel oil, carrot oil, coconut oil, mango butter, evening primrose oil, black currant oil, avocado oil, microcrystalline wax, paraffin, petrolatum, petroleum jelly, ozokerite, montan wax, beeswax, lanolin or a derivative, candelilla wax, ouricury wax, carnauba wax, Japan wax, cocoa butter, sugarcane wax, cork fiber wax, and mixtures thereof.

3. (Original) The composition according to claim 1 wherein the pharmaceutically acceptable carrier is cocoa butter.

4. (Original) The composition according to claim 1 wherein

a. said 3-omega oils are present in a total weight ranging from about 500 mg to about 2000 mg, said gamma-linoleic acid is present in an amount ranging from about 15% to about 30% by weight, said eicosapentanoic acid from molecularly distilled fish oil is present in an amount ranging from about 30% to about 50% by weight, and said docosahexaenoic acid from molecularly distilled fish oil is present in an amount ranging from about 30% to about 50% by weight.

b. said tocopherol is present in an amount between about 1000 IU and about 15000 IU;

c. said lavender oil is present in an amount up to about 600 mcg;

d. about 120 ml of pharmaceutically acceptable carrier.

5. (Original) The composition according to claim 1 wherein:

a. said molecularly distilled 3-omega fish oils are present in a total weight of about 1000 mg, said gamma-linoleic acid is present in an amount of about 20% by weight; said eicosapentanoic acid from molecularly distilled fish oil is present in an amount of about 40% by weight; said docosahexaenoic acid from molecularly

distilled fish oil is present in an amount of about 40% by weight;

b. said tocopherol is present in an amount of about 5600 IU;

c. said lavender oil is present in an amount of about 300 mcg;

d. in about 120 ml of pharmaceutically acceptable carrier.

6. (Original) The composition according to claim 5 wherein the tocopherol is alpha-tocopheryl acetate and the pharmaceutically acceptable carrier is cocoa butter.

7. (Original) A composition for soothing traumatic conditions of the skin comprising:

a. omega-3 fish oils having a total weight of up to about 3000 mg, consisting of gamma-linoleic acid (GLA) in an amount ranging from about 10% to about 40% by weight, eicosapentanoic acid (EPA) from molecularly distilled fish oil in an amount ranging from about 20% to about 60% by weight, and docosahexaenoic acid (DHA) from molecularly distilled fish oil an amount ranging from about 20% to about 60% by weight;

b. mixed tocopherols in an amount of up to about 20,000 IU;

c. lavender oil in an amount of up to about 1 mg;

d. Sodium-PCA in an amount of up to about 1 g;

e. about 120 ml of a pharmaceutically acceptable carrier.

8. (Original) The composition according to claim 7 wherein said Sodium PCA is present in an amount up to about 0.5 g.

9. (Original) The composition according to claim 8 wherein said Sodium PCA is present in an amount of about 0.25 g.

10. (Original) A composition for soothing traumatic conditions of the skin comprising:

a. omega-3 oils having a total weight of up to about 3000 mg, consisting of gamma-linoleic acid (GLA) in an amount ranging from about 10% to about 40% by weight, eicosapentanoic acid (EPA) from molecularly distilled fish oil in an

amount ranging from about 20% to about 60% by weight, and docosahexaenoic acid (DHA) from molecularly distilled fish oil an amount ranging from about 20% to about 60% by weight;

b. mixed tocopherols in an amount of up to about 20,000 IU;

c. lavender oil in an amount of up to about 1 mg;

d. Methyl-Sulfonyl-Methane in an amount of about 6 g to about 18 g;

e. about 120 ml of a pharmaceutically acceptable carrier.

11. (Original) The composition according to claim 10 wherein the Methyl-Sulfonyl-Methane is present in an amount of about 9 g to about 15 g.

12. (Original) The composition according to claim 10 wherein the Methyl-Sulfonyl-Methane is present in an amount of about 12 g.

13. (Original) A topical composition according to claim 1, characterized in that it is active against radiation dermatitis.

14. (Original) A topical composition according to claim 1, characterized in that it is active against exposure-induced wrinkles.

15. (Original) A topical composition according to claim 1, characterized in that it is active against thermal burns.

16. (Original) A topical composition according to claim 1, characterized in that it is active against sunburn.

17. (Original) The topical composition according to claim 1, characterized in that is active against dermatomyofibromas.

18. (Cancelled) A method of treating traumatic conditions of the skin of a human comprising

topical application of the composition of claim 1 to the affected areas of the skin.

19. (Cancelled) The method according to claim therein said traumatic condition of the skin is radiation dermatitis.

20. (Cancelled) The method according to claim 19 wherein said topical application is performed immediately after radiation treatments and repeated from once to three times daily through out the course of radiation.

21. (Cancelled) The method according to claim 20 wherein said topical application is performed immediately after radiation treatments and repeated twice daily throughout the course of radiation.

22. (Cancelled) The method according to claim 18 wherein said traumatic condition of the skin is a thermal burn.

23. (Cancelled) The method according to claim 22 wherein said topical application is performed immediately after the burn is experienced and repeated from one to three times daily until the skin heals.

24. (Cancelled) The method according to claim 18 wherein said traumatic condition of the skin is one or more dermatomyofibromas.

25. (Cancelled) The method according to claim 24 wherein said affected areas of the skin are newly discovered lesions.

26. (Cancelled) The method according to claim 25 wherein said topical application is performed as soon as a newly discovered lesion is noted and repeated from one to five times daily until the skin heals.

27. (Cancelled) The method according to claim 26 wherein said topical application is performed as soon as a newly discovered lesion is observed and repeated three times daily until the skin heals.

28. (Cancelled) A method of treating exposure-induced wrinkles of the skin of a human comprising the topical application of the composition of claim 1 to the face of a human.

29. (Cancelled) The method according to claim 28 wherein said topical application is performed one to two times daily.

II. Remarks

These amendments were made to respond to restriction and election of species requirement and do not narrow of limit the scope of selected claims. Applicant submits that these amendments place his application in condition for allowance.

III. Extension of Time Request

The Office Action was written on June 23, 2005. Applicant believes the 3 month period expired on July 23 that fees for a small entity, for the one month extension for time to respond are $60 within the first month are necessary, and this and any additional fees are to be taken from deposit account number 50-1726.

Dated and mailed August 19, 2005

Respectfully Submitted,



August 19, 2005
Date

Nancy Lord
Reg. No. 45462

Nancy Lord
5079 N. Dixie Highway, No. 334
Oakland Park, 33334
Tel. 775-253-0137